Results of the PRESTOCON preclinical trial are in
Results of the PRESTOCON preclinical trial are in
The results of the PRESTOCON preclinical trial have demonstrated that Panax ginseng and Gingko biloba extracts have a well-documented safety profile and are well tolerated for the treatment of moderate-to-severe disease.
In addition, the trial provided useful insights into the application of Panax ginseng (G115) and Gingko biloba (GK501) as novel and natural therapeutic intervention for the treatment of cognitive-related diseases.
These findings support the idea that the combination may become a valid and safe therapeutic intervention in the treatment of neurological disorders.
Robert Hendriks MD
Chief Executive Officer, SFI Health
Learn
Research is important, and we want to share it. Our articles distill the complex research and offer expert analysis on the microbiome, brain health and wellbeing.
Promising results from a preliminary study evaluating the impact of long-chain polyunsaturated fatty acids on reading and writing skills in...
New study links omega-3 fatty acids to improved reading and writing skills in children through key neurocognitive processes.
Read more
Managing mental overload with cognitive load therapy
Mental fatigue from cognitive overload is common; therapy based on cognitive load theory can help reduce stress and improve wellbeing.
Read more
How to use AI to strengthen your cognition – not replace it
Is AI beginning to reshape how we think? The opportunity lies in using it to stimulate - not substitute - our cognition.
Read more